Immunocore Holdings (IMCR) Current Assets (2019 - 2026)

Immunocore Holdings (IMCR) has reported Current Assets for 8 consecutive years, with $1.0 billion the latest figure, recorded in Q1 2026.

• Quarterly Current Assets rose 5.82% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 5.82% YoY) and the FY2025 annual result came in at $996.7 million, up 7.19% from the prior year.
• Current Assets grew to $1.0 billion in Q1 2026 per IMCR's latest filing, from $996.7 million in the prior quarter.
• Over the last five years, Current Assets for IMCR reached as high as $1.0 billion in Q3 2025 and fell as low as $459.6 million in Q4 2022.
• A 5-year average of $827.0 million and a median of $948.6 million in 2025 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets surged 93.56% — and 2025, when it rose 1.68%.
• Year by year, Current Assets stood at $459.6 million in 2022, then grew by 15.05% to $528.8 million in 2023, then soared by 75.84% to $929.9 million in 2024, then grew by 7.19% to $996.7 million in 2025, then climbed by 0.71% to $1.0 billion in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $1.0 billion, $996.7 million, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.